메뉴 건너뛰기




Volumn 32, Issue 8, 2011, Pages 450-459

Peroral and intravenous iron preparations - similarities, differences and perspectives;Peroral und intravenös anwendbare Eisenpräparate - Gemeinsamkeiten, unterschiede und perspektiven

Author keywords

Approval regulatories; Intravenous iron carbonhydrate complexes; Iron deficiencies; Pharmacological differences

Indexed keywords

FERRIC CHLORIDE; FERROUS CHLORIDE;

EID: 80051916527     PISSN: 01737597     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (12)

References (52)
  • 3
    • 62349104137 scopus 로고    scopus 로고
    • Pathophysiologisch-orientierte Diagnostik und Therapie der Eisenmangelanämie bei chronisch entzündlichen Darmerkrankungen
    • Stein JM, Hartmann F, Cordes HJ, et al. Pathophysiologisch-orientierte Diagnostik und Therapie der Eisenmangelanämie bei chronisch entzündlichen Darmerkrankungen. Z Gastroenterol 2009;47:228-36.
    • (2009) Z Gastroenterol , vol.47 , pp. 228-236
    • Stein, J.M.1    Hartmann, F.2    Cordes, H.J.3
  • 4
    • 64349113606 scopus 로고    scopus 로고
    • Iron deficiency anemia: Diagnosis and management
    • Clark SF. Iron deficiency anemia: diagnosis and management. Curr Opin Gastroenteral 2009;25:122-8.
    • (2009) Curr Opin Gastroenteral , vol.25 , pp. 122-128
    • Clark, S.F.1
  • 5
    • 33750584843 scopus 로고    scopus 로고
    • Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation, and hemodialysis
    • DOI 10.1002/ajh.20657
    • Malyszko J, Malyszko JS, Pawlak K, et al. Hepcidin, iron status, and renal function in chronic renal failure, kidney transplantation and hemodialysis. Am J Hematol 2006;81:832-7. (Pubitemid 44682184)
    • (2006) American Journal of Hematology , vol.81 , Issue.11 , pp. 832-837
    • Malyszko, J.1    Malyszko, J.S.2    Pawlak, K.3    Mysliwiec, M.4
  • 6
    • 33645291842 scopus 로고    scopus 로고
    • Neue Parameter zur Diagnostik von Eisenmangelzuständen
    • Thomas L, Thomas C, Heimpel H. Neue Parameter zur Diagnostik von Eisenmangelzuständen. Dt Ärzteblatt 2005;104:1580-6.
    • (2005) Dt Ärzteblatt , vol.104 , pp. 1580-1586
    • Thomas, L.1    Thomas, C.2    Heimpel, H.3
  • 7
  • 8
    • 0024360830 scopus 로고
    • Clinical pharmacokinetics of iron preparations
    • Harju E. Clinical pharmacokinetics of iron preparations. Clin Pharmacokinet 1989;17:69-89. (Pubitemid 19199634)
    • (1989) Clinical Pharmacokinetics , vol.17 , Issue.2 , pp. 69-89
    • Harju, E.1
  • 9
    • 0022576447 scopus 로고
    • BIOVERFUGBARKEIT UND THERAPEUTISCHER WERT ORALER EISEN(II)- UND EISEN(III)-PRAPARATE
    • Heinrich H. Bioverfügbarkeit und therapeutischer Wert oraler Eisen(II)- und Eisen(III)-Präparate. Dtsch Apoth Ztg 1986;14:681-90. (Pubitemid 16102271)
    • (1986) Deutsche Apotheker Zeitung , vol.126 , Issue.14 , pp. 681-690
    • Heinrich, H.C.1
  • 10
    • 77951785290 scopus 로고    scopus 로고
    • Orange but not apple juice enhances ferrous fumarate absorption in small children
    • Balay KS, Hawthorne KM, Hicks PD, et al. Orange but not apple juice enhances ferrous fumarate absorption in small children. J Pediatr Gastroenterol Nutr 2010;50:545-50.
    • (2010) J Pediatr Gastroenterol Nutr , vol.50 , pp. 545-550
    • Balay, K.S.1    Hawthorne, K.M.2    Hicks, P.D.3
  • 11
    • 34447345399 scopus 로고    scopus 로고
    • Safety and efficacy of iron (III)-hydroxide polymaltose complex: A review of over 25 years experience
    • Geisser P. Safety and efficacy of iron(III)-hydroxide polymaltose complex / a review of over 25 years experience. Arzneimittelforschung 2007;57:439-52. (Pubitemid 47055995)
    • (2007) Arzneimittel-Forschung/Drug Research , vol.57 , Issue.6 A , pp. 439-452
    • Geisser, P.1
  • 12
    • 0034095717 scopus 로고    scopus 로고
    • Better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia
    • Jacobs P, Wood L, Bird AR. Better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anemia. Hematology 2000;5:77-83. (Pubitemid 30410508)
    • (2000) Hematology , vol.5 , Issue.1 , pp. 77-83
    • Jacobs, P.1    Wood, L.2    Bird, A.R.3
  • 13
    • 0033181106 scopus 로고    scopus 로고
    • Oral supplementation with ferrous sulfate but not with nonionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation
    • DOI 10.1016/S0271-5317(99)00073-1, PII S0271531799000731
    • Tuomainen TP, Nyyssönen K, Porkkala-Sarataho E, et al. Oral supplementation with ferrous transfer but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation. Nutrition Research 1999;19:1121-32. (Pubitemid 29297738)
    • (1999) Nutrition Research , vol.19 , Issue.8 , pp. 1121-1132
    • Tuomainen, T.-P.1    Nyyssonen, K.2    Porkkala-Sarataho, E.3    Salonen, R.4    Baumgartner, J.A.5    Geisser, P.6    Salonen, J.T.7
  • 14
    • 37349054566 scopus 로고    scopus 로고
    • Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease
    • Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006;47(Suppl. 3):33-53.
    • (2006) Am J Kidney Dis , vol.47 , Issue.SUPPL. 3 , pp. 33-53
  • 15
    • 33646246606 scopus 로고    scopus 로고
    • Parenterale kolloidale Eisenkomplexprä parate
    • Jahn M, Roth S, Langguth P. Parenterale kolloidale Eisenkomplexprä parate. Dtsch Apoth Ztg 2006;146;1510-8.
    • (2006) Dtsch Apoth Ztg , vol.146 , pp. 1510-1518
    • Jahn, M.1    Roth, S.2    Langguth, P.3
  • 16
    • 77958585184 scopus 로고    scopus 로고
    • Clinical and economic outcomes in medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: The role of intravenous iron therapy
    • Knight TG, Ryan K, Schaefer CP, D'Sylva L, et al. Clinical and economic outcomes in medicare beneficiaries with stage 3 or stage 4 chronic kidney disease and anemia: the role of intravenous iron therapy. J Manag Care Pharm 2010;16:605-15.
    • (2010) J Manag Care Pharm , vol.16 , pp. 605-615
    • Knight, T.G.1    Ryan, K.2    Schaefer, C.P.3    D'Sylva, L.4
  • 17
    • 49649099818 scopus 로고    scopus 로고
    • Ferumoxytol for treating iron deficiency anemia in CKD
    • Spinowitz BS, Kausz A, Baptista J, et al. Ferumoxytol for treating iron deficiency anemia in CKD. J Am Soc Nephrol 2008;19:1599-605.
    • (2008) J Am Soc Nephrol , vol.19 , pp. 1599-1605
    • Spinowitz, B.S.1    Kausz, A.2    Baptista, J.3
  • 18
    • 77956806828 scopus 로고    scopus 로고
    • The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: A review
    • Quinibi WY. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung 2010;60:399-412.
    • (2010) Arzneimittelforschung , vol.60 , pp. 399-412
    • Quinibi, W.Y.1
  • 19
    • 9644257204 scopus 로고    scopus 로고
    • Structure, chemistry, and pharmacokinetics of intravenous iron agents
    • DOI 10.1097/01.ASN.0000143814.49713.C5
    • Danielson BG. Structure, chemistry, and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol 2004;15:S93-S98. (Pubitemid 39578822)
    • (2004) Journal of the American Society of Nephrology , vol.15 , Issue.SUPPL. 2
    • Danielson, B.G.1
  • 20
    • 39349083683 scopus 로고    scopus 로고
    • Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations
    • Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Altern Transfus Med. 2007;9:37-42.
    • (2007) Transfus Altern Transfus Med , vol.9 , pp. 37-42
    • Moniem, K.A.1    Bhandari, S.2
  • 21
    • 0036280354 scopus 로고    scopus 로고
    • Parenteral iron formulations: A comperative toxicologic analysis and mechanisms of cell injury
    • Zager RA, Johnson ACM, Hanson SY, et al. Parenteral iron formulations: A comperative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40:90-103.
    • (2002) Am J Kidney Dis , vol.40 , pp. 90-103
    • Zager, R.A.1    Johnson, A.C.M.2    Hanson, S.Y.3
  • 22
    • 77955248295 scopus 로고    scopus 로고
    • A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy
    • Khalafallah A, Dennis A, Bates J, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med 2010;268:286-95.
    • (2010) J Intern Med , vol.268 , pp. 286-295
    • Khalafallah, A.1    Dennis, A.2    Bates, J.3
  • 24
    • 80051920039 scopus 로고    scopus 로고
    • Safety Evaluation of Iron (Ferrlecit®, DexFerrum®, INFeD®) from 21,060,000 doses administered i.v., in the US 1998-2000
    • Ahlmén J, Vaage-Nilsen O. Safety Evaluation of Iron (Ferrlecit®, DexFerrum®, INFeD®) from 21,060,000 doses administered i.v., in the US 1998-2000. Nephrol Dial Transplant 2002;133:M305.
    • (2002) Nephrol Dial Transplant , vol.133
    • Ahlmén, J.1    Vaage-Nilsen, O.2
  • 27
    • 39349106653 scopus 로고    scopus 로고
    • Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease
    • DOI 10.1038/sj.ki.5002779, PII 5002779
    • Auerbach M, Al Talib K. Low-molecular-weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease. Kidney Int 2008;73:528-30. (Pubitemid 351264124)
    • (2008) Kidney International , vol.73 , Issue.5 , pp. 528-530
    • Auerbach, M.1    Al, T.K.2
  • 28
    • 77956855555 scopus 로고    scopus 로고
    • Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: A review of randomized controlled trials across different indications
    • Bailie GR. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications. Arzneimittelforschung 2010;60:386-98.
    • (2010) Arzneimittelforschung , vol.60 , pp. 386-398
    • Bailie, G.R.1
  • 29
    • 77956860272 scopus 로고    scopus 로고
    • The new generation of intravenous iron: Chemistry, pharmacology, and toxicology of ferric carboxymaltose
    • Funk F, Ryle P, Canclini C, et al. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung 2010;60:345-53.
    • (2010) Arzneimittelforschung , vol.60 , pp. 345-353
    • Funk, F.1    Ryle, P.2    Canclini, C.3
  • 30
    • 1342306211 scopus 로고    scopus 로고
    • Labile iron in parenteral iron formulations: A quantitative and comparative study
    • DOI 10.1093/ndt/gfg579
    • Van Wyck D, Anderson J, Johnson K. Labile iron in parenteral iron formulation: a quantitative and comparative study. Nephrol Dial Transplant 2004;19:561-5. (Pubitemid 38263113)
    • (2004) Nephrology Dialysis Transplantation , vol.19 , Issue.3 , pp. 561-565
    • Van Wyck, D.B.1    Anderson, J.2    Johnson, K.3
  • 31
    • 0029980758 scopus 로고    scopus 로고
    • "Oversaturation" of transferring after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients
    • Zanen AL, Adriaansen HJ, van Bommel EFH, et al. " Oversaturation" of transferring after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 1996;11:820-4.
    • (1996) Nephrol Dial Transplant , vol.11 , pp. 820-824
    • Zanen, A.L.1    Adriaansen, H.J.2    Van Bommel, E.F.H.3
  • 32
    • 33847282976 scopus 로고    scopus 로고
    • Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis
    • DOI 10.1592/phco.27.3.343
    • Pai AB, Boyd AV, McQuade CR, et al. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007;27:343-50. (Pubitemid 46327902)
    • (2007) Pharmacotherapy , vol.27 , Issue.3 , pp. 343-350
    • Pai, A.B.1    Boyd, A.V.2    McQuade, C.R.3    Harford, A.4    Norenberg, J.P.5    Zager, P.G.6
  • 33
    • 79952200956 scopus 로고    scopus 로고
    • Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds
    • Toblli JE, Cao M, Olivieri L, Angerosa M. Comparison of the renal, cardiovascular and hepatic toxicity data of original intravenous iron compounds. Nephrol Dial Transplant 2010;25:3631-40.
    • (2010) Nephrol Dial Transplant , vol.25 , pp. 3631-3640
    • Toblli, J.E.1    Cao, M.2    Olivieri, L.3    Angerosa, M.4
  • 34
    • 77955456688 scopus 로고    scopus 로고
    • Parenteral iron formulations differentially affect MCP-1, HO-1 and NGAL gene expression and renal responses to injury
    • Johnson ACM, Becker K, Zager RA. Parenteral iron formulations differentially affect MCP-1, HO-1 and NGAL gene expression and renal responses to injury. Am J Physiol Renal Physiol 2010;299:426-35.
    • (2010) Am J Physiol Renal Physiol , vol.299 , pp. 426-435
    • Johnson, A.C.M.1    Becker, K.2    Zager, R.A.3
  • 35
    • 0031753685 scopus 로고    scopus 로고
    • Saccharated ferric oxide-induced osteomalacia in Japan: Iron-induced osteopathy due to nephropathy
    • Sato K, Shiraki M. Saccharated ferric oxide-induced osteomalacia in Japan: Iron-induced osteopathy due to nephropathy. Endocrine J 1998;45:431-9. (Pubitemid 28477653)
    • (1998) Endocrine Journal , vol.45 , Issue.4 , pp. 431-439
    • Sato, K.1    Shiraki, M.2
  • 37
    • 74049101227 scopus 로고    scopus 로고
    • Differences between the original iron sucrose complex Venofer® and the iron sucrose similar Generis®, and potential implications
    • Toblli Je, Cao G, Oliveri L, et al. Differences between the original iron sucrose complex Venofer® and the iron sucrose similar Generis®, and potential implications. Port J Nephrol Hypert 2009;23:53-63.
    • (2009) Port J Nephrol Hypert , vol.23 , pp. 53-63
    • Toblli, Je.1    Cao, G.2    Oliveri, L.3
  • 38
    • 80051928987 scopus 로고    scopus 로고
    • Inflammatory response of generic iron sucrose complex preparations in kidney, liver and heart of normal rats
    • Toblli JE, Cao G, Olivieri L, et al. Inflammatory response of generic iron sucrose complex preparations in kidney, liver and heart of normal rats. Nephrol Dial Transplant 2006;21:160.
    • (2006) Nephrol Dial Transplant , vol.21 , pp. 160
    • Toblli, J.E.1    Cao, G.2    Olivieri, L.3
  • 39
    • 66149166994 scopus 로고    scopus 로고
    • Differences between Original Intravenous Iron Sucrose and Iron Sucrose Similar Preparations
    • Toblli Je, Cao M, Oliveri L. Differences Between Original Intravenous Iron Sucrose and Iron Sucrose Similar Preparations. Arzneimittelforschung 2009;59:176-190.
    • (2009) Arzneimittelforschung , vol.59 , pp. 176-190
    • Toblli, Je.1    Cao, M.2    Oliveri, L.3
  • 40
    • 54349090164 scopus 로고    scopus 로고
    • Intravenous versus oral iron supplementation for the treatment of anemia in CKD: Systematic review and metaanalysis
    • Rosen-Zvi B, Gafter-Gvili A, Paul M, et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and metaanalysis. Am J Kidney Dis 2008;52:897-906.
    • (2008) Am J Kidney Dis , vol.52 , pp. 897-906
    • Rosen-Zvi, B.1    Gafter-Gvili, A.2    Paul, M.3
  • 41
    • 77956857469 scopus 로고    scopus 로고
    • Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: A dose-escalation study in volunteers with mild iron-deficiency anaemia
    • Geisser P, Banké-Bochita J. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia. Arzneimittelforschung 2010;60:362-72.
    • (2010) Arzneimittelforschung , vol.60 , pp. 362-372
    • Geisser, P.1    Banké-Bochita, J.2
  • 42
    • 75149167105 scopus 로고    scopus 로고
    • Ferumoxytol: A new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease
    • Schwenk MH. Ferumoxytol: A new intravenous iron preparation for the treatment of iron deficiency anemia in patients with chronic kidney disease. Pharmacotherapy 2010;30:70-9.
    • (2010) Pharmacotherapy , vol.30 , pp. 70-79
    • Schwenk, M.H.1
  • 43
    • 77956802593 scopus 로고    scopus 로고
    • Pharmacodynamics and safety of ferric carboxymaltose: A multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder
    • Geisser P, Rumyantsev V. Pharmacodynamics and safety of ferric carboxymaltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastrointestinal disorder. Arzneimittelforschuhg 2010;60:373-85.
    • (2010) Arzneimittelforschuhg , vol.60 , pp. 373-385
    • Geisser, P.1    Rumyantsev, V.2
  • 44
    • 72449156527 scopus 로고    scopus 로고
    • Ferric carboxymaltose in patients with heart failure and iron deficiency
    • Anker SD, Colet JC, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:1-13.
    • (2009) N Engl J Med , vol.361 , pp. 1-13
    • Anker, S.D.1    Colet, J.C.2    Filippatos, G.3
  • 46
    • 52949101033 scopus 로고    scopus 로고
    • Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: A randomized controlled clinical trial
    • Seid MH, et al. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol 2008;199;435:e1-7.
    • (2008) Am J Obstet Gynecol , vol.199 , Issue.435
    • Seid, M.H.1
  • 47
    • 71849101678 scopus 로고    scopus 로고
    • Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: A randomized, controlled trial
    • Van Wyck DB, Mangione A, Morrison J. et al. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion 2009;49:2719-28.
    • (2009) Transfusion , vol.49 , pp. 2719-2728
    • Van Wyck, D.B.1    Mangione, A.2    Morrison, J.3
  • 48
    • 34548462994 scopus 로고    scopus 로고
    • Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: A randomized controlled trial
    • DOI 10.1097/01.AOG.0000275286.03283.18, PII 0000625020070800000009
    • Van Wyck DB, Martens MG, Seid MH, et al. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia. Obstet Gynecol 2007;110:267-78. (Pubitemid 47356650)
    • (2007) Obstetrics and Gynecology , vol.110 , Issue.2 I , pp. 267-278
    • Van Wyck, D.B.1    Martens, M.G.2    Seid, M.H.3    Baker, J.B.4    Mangione, A.5
  • 49
    • 40949107423 scopus 로고    scopus 로고
    • 2. Aufl. Börm Bruckmeier Verlag
    • M. Imohl (Hrsg.). Labormedizin pocket. 2. Aufl. 2005; Börm Bruckmeier Verlag.
    • (2005) Labormedizin Pocket
    • Imohl, M.1
  • 50
    • 80051937177 scopus 로고    scopus 로고
    • Hepcidin: Clinical utility as a diagnostic tool and therapeutic target
    • Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int 2011;79:1
    • (2011) Kidney Int , vol.79 , pp. 1
    • Coyne, D.W.1
  • 51
    • 80051940762 scopus 로고    scopus 로고
    • Do two intravenous iron sucrose preparations have the same efficacy?
    • Feb 25 [epub ahead of print]
    • Rottembourg J, Kadri A, Leonard E, Dansaert A, et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant 2011 Feb 25 [epub ahead of print].
    • (2011) Nephrol Dial Transplant
    • Rottembourg, J.1    Kadri, A.2    Leonard, E.3    Dansaert, A.4
  • 52
    • 79951865444 scopus 로고    scopus 로고
    • A comperative look at the safety profiles of intravenous iron products used in the hemodialysis population
    • Coppol E, Shelly J, Cheng S, Kaakeh Y, et al. A comperative look at the safety profiles of intravenous iron products used in the hemodialysis population. Ann Pharmacother 2011;45:241-7.
    • (2011) Ann Pharmacother , vol.45 , pp. 241-247
    • Coppol, E.1    Shelly, J.2    Cheng, S.3    Kaakeh, Y.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.